A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

ABSTRACT: BACKGROUND:Inhibition of the epidermal growth factor receptor (EGFR) extends patient survival in multiple tumor types. Skin toxicities are the most common adverse event (AE) elicited by EGFR inhibitors. Here, we provide deeper insights into patients' and physicians' acceptance of the risk/benefit trade-offs of skin toxicities during cancer therapy, including comparison of their perceptions and experiences with dermatologic AEs. METHODS:A multinational survey of 195 patients and 120 physicians was conducted to gauge attitudes regarding skin toxicities as an AE during cancer therapy. RESULTS:Skin toxicities were identified by patients and physicians as the AE that is most discouraging to patients when undergoing cancer therapies. Skin toxicities were cited as causing pain, impairing quality

SUBMITTER: Tischer B 

PROVIDER: S-EPMC5847041 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature